Analytical Data
-
Gene name
DCD
-
简介
The DCD protein is found in sweat and has antimicrobial activity against Escherichia coli, Enterococcus faecalis, Staphylococcus aureus, and Candida albicans. DCD Protein, Human (P.pastoris, His) is the recombinant human-derived DCD protein, expressed by P. pastoris , with N-6*His labeled tag.
- Application
-
Alternative Names
AIDD ; DCD 1; dcd; DCD-1; DCD_HUMAN; Dermcidin; DSEP; HCAP; PIF; Preproteolysin
-
Species
Human
-
Source
P. pastoris
-
Tag
N-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P81605-1
-
Expression Region
Y20-L110
-
Protein Length
Full Length of Isoform-1 Mature Protein
-
Molecular Weight
17 kDa. The reducing (R) protein migrat es as 17 kDa in SDS-PAGE may be due to relative charge.
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DCD (Defensins Cystine-rich Domain) recombinant proteins have garnered significant attention in scientific research due to their potential applications in various fields, including immunology, cancer therapy, and antimicrobial treatment. Defensins are small, cysteine-rich peptides produced by various organisms, primarily as a part of the innate immune system, to combat pathogens. The ability to produce DCD recombinant proteins in the laboratory has revolutionized our understanding of their structure, function, and potential therapeutic uses. Researchers aim to investigate the mechanisms by which DCD peptides exert their antimicrobial effects and their role in modulating immune responses. Furthermore, the unique properties of DCD proteins, such as their stability and ability to form multi-disulfide bonds, make them ideal candidates for developing new drugs or vaccines. Recent studies have also focused on engineering DCD proteins to enhance their efficacy or to target specific cells, which could lead to breakthroughs in treating infections and specific types of cancers. By unraveling the complexities of DCD proteins, scientists hope to harness their capabilities for medical applications, paving the way for innovative therapies that address pressing health challenges.
